Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations. by Burke, G et al.
Available online at www.sciencedirect.comwww.elsevier.com/locate/nmd
Neuromuscular Disorders 23 (2013) 170–175Salbutamol beneﬁts children with congenital myasthenic syndrome
due to DOK7 mutations
Georgina Burke a,⇑, Andrew Hiscock b, Andrea Klein c, Erik H. Niks d, Marion Main b,
Adnan Y. Manzur b, Joanne Ng e, Catherine de Vile e, Francesco Muntoni b,
David Beeson f, Stephanie Robb b
aWessex Neurological Centre, Southampton General Hospital, Southampton, UK
bDubowitz Neuromuscular Centre, UCL Institute of Child Health and Great Ormond Street Hospital, London, UK
cUniversity Children’s Hospital, Zurich, Switzerland
dDepartment of Neurology, Leiden University Medical Center, Leiden, The Netherlands
eDepartment of Neurology, Great Ormond Street Hospital, London, UK
fWeatherall Institute of Molecular Medicine, John Radcliﬀe Hospital, Oxford, UK
Received 1 June 2012; received in revised form 25 September 2012; accepted 6 November 2012Abstract
Congenital myasthenic syndromes due to DOK7 mutations cause fatigable limb girdle weakness. Treatment with ephedrine improves
muscle strength. Salbutamol, a b2-adrenergic receptor agonist with fewer side eﬀects and more readily available, has been eﬀective in
adult and anecdotal childhood cases. This study reports the eﬀects of salbutamol on motor function in childhood DOK7 congenital
myasthenic syndrome. Nine children (age range 5.9–15.1 years) were treated with oral salbutamol, 2–4 mg TDS. The eﬀect on timed
tests of motor function, pre- and up to 28 months post-treatment, was audited retrospectively. All 9 reported functional beneﬁt
within 1 month, with progressive improvement to a plateau at 12–18 months. Within the ﬁrst month, all 3 non-ambulant children
resumed walking with assistance. Although improvements were seen in some timed tests (timed 10 m, arm raise time, 6 min walk
time) this did not fully reﬂect the observed functional beneﬁts in daily living activities. No major side eﬀects were reported. We
conclude that oral salbutamol treatment signiﬁcantly improves strength in children with DOK7 congenital myasthenic syndrome and
is well tolerated. Outcome measures need to be reﬁned further, both to accurately reﬂect functional abilities in children and to
document progress and treatment response.
 2012 Elsevier B.V. All rights reserved.
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Mutations in DOK7, encoding the skeletal muscle adap-
tor protein Dok-7, result in congenital myasthenic
syndrome (CMS) associated with small, simpliﬁed neuro-
muscular junctions [1]. The resulting phenotype is variable,0960-8966/$ - see front matter  2012 Elsevier B.V. All rights reserved.
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E-mail address: georgina.burke@uhs.nhs.uk (G. Burke).but typically patients present in childhood with a limb-gir-
dle pattern of weakness and ptosis. Ophthalmoplegia is
rare but progressive respiratory impairment frequently
occurs. Treatment with cholinesterase inhibitors is ineﬀec-
tive and response to 3,4-diaminopyridine variable [2–4].
Ephedrine has been shown to be helpful, with patients
reporting an improvement over a 1–24 month period
[5,6]. However, ephedrine has both a and b-adrenergic
eﬀects and concern remains regarding central and cardiac
adverse eﬀects, particularly with long term use in children.
Salbutamol, a selective b2 agonist, has been used
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tor to treat asthma and, more recently, to improve muscle
strength in SMA [7] and some congenital myopathies [8,9],
with a good safety proﬁle. In the USA, where ephedrine is
no longer available, it was postulated that salbutamol may
have similar beneﬁt to ephedrine in CMS and this has
recently been conﬁrmed in an open label study of predom-
inantly adults with DOK7 synaptopathy, with patient
reported functional improvement on albuterol, the USA
equivalent of salbutamol [10]. Although ephedrine is still
available in the UK, we oﬀer salbutamol as ﬁrst line treat-
ment to children (including infants) with DOK7 CMS, to
reduce the potential for a-adrenergic side eﬀects. In our
multidisciplinary paediatric myasthenia clinics, children
are assessed regularly with objective timed measures of fati-
gue and functional motor ability, in addition to detailed
clinical review. The timed tests used are targeted to be
brief, to maintain interest and motivation in younger chil-
dren and are easily administered in the clinic setting. Here
we present a retrospective review of the eﬀect of salbutamol
on functional ability and timed tests in nine children with
DOK7 mutations followed in our clinics for up to
28 months.
2. Patients and methods
2.1. Patients
This is a retrospective case review of clinical data and
timed tests of muscle fatigability recorded at routine clinic
visits. The study was approved by the Clinical Audit Team
at Great Ormond Street Hospital. Nine children from eight
unrelated families with genetically conﬁrmed DOK7 muta-
tions were included. Molecular analysis of the DOK7 gene
was performed by the Oxford NCG service as previously
described [1]. All mutations have been previously reported.
Patient 8 had received pyridostigmine from the age of
17 months with some improvement initially but she
remained non-ambulant. The pyridostigmine was stopped
3 months after salbutamol was started, with no decline in
functional ability. Patient 2 had received ephedrine from
the age of 8.3 years but due to parental choice it was chan-
ged to salbutamol after 7 months. None of the other chil-
dren had received pharmaceutical treatment for their
congenital myasthenia before commencing salbutamol.
Prior to starting oral salbutamol, each child had detailed
clinical review, cardiac examination, baseline BP and 12
lead ECG. Three had transthoracic echocardiograms. Chil-
dren aged 5–8 years were prescribed salbutamol liquid,
1 mg TDS for 1 week, increasing to 2 mg TDS thereafter.
Older children were oﬀered slow release salbutamol tablets,
4 mg once daily, increasing after 1 week to 4 mg twice
daily. The 15 year old boy, unable to swallow tablets, took
salbutamol liquid 4 mg TDS. Each child was longitudinally
assessed clinically, using the medical research council
(MRC) scale of muscle strength, BP, heart rate and spirom-
etry to assess vital capacity.2.2. Timed assessments
The following timed tests of motor function and muscle
fatigability were performed where possible: timed rise from
sitting on the ﬂoor, timed 10 m walk, maximum time main-
taining 90 forward ﬂexion of the right arm at the shoulder
(up to 120 s), number of repeated sit to stand from a chair
(in 1 min) and grip myometry (Newtons) using a Citec
hand held dynanmometer (C.I.T. Technics, Netherlands).
During the study period we also introduced a 6 min walk
time assessment, performed according to standard proto-
cols, in those clinics where the facility was available and
the children were able to walk that distance. Accordingly,
full results including baseline pre-treatment were only
achieved for patient 4.
Children were evaluated at baseline pre-treatment, at 1–
3 months, 6–8 months and approximately 6 monthly post-
treatment thereafter. ECG was repeated at 1–3 months,
then yearly.
3. Results
Nine children (6 females and 3 males) from eight unre-
lated families were included in the study. Patients 4 and 5
are sisters. Clinical demographics are shown in Table 1.
Their age at starting salbutamol ranged from 5.9 years to
15.1 years. Six had symptoms from birth but genetically
conﬁrmed diagnoses were delayed in all. All had limb girdle
weakness and three were non-ambulant at baseline
(patients 6, 7 and 8). The non-ambulant children had knee
and hip ﬂexion contractures and patient 7 had undergone
spinal surgery for scoliosis. In addition to limb girdle weak-
ness, facial weakness (8/9) and ptosis (6/9) were common,
but ophthalmoplegia (2/9) was rare and consisted of lim-
ited upgaze only. This is consistent with the phenotype
described by others [2,3].
3.1. Eﬀect of salbutamol on functional ability
All families reported functional improvement within one
month of starting salbutamol. Onset of improvement was
noted as early as 2 weeks, with a gradual increase to a pla-
teau at 6–18 months. Ambulant children reported
improved endurance for distances, ability to run and climb
stairs (previously not possible in some) and fewer falls. One
no longer had ﬂuctuation in motor abilities. The three non-
ambulant children resumed walking: within 2 weeks of
starting salbutamol patient 5 could rise from the ﬂoor,
walk with a crutch and go upstairs – he now walks 30 m
unaided. Patient 6 was able to stand and walk assisted after
1 month of treatment, took 30 steps unaided at 7 months
and now can walk at least 10 m unaided. Patient 8 at
1 month of treatment was able to take 23 steps with hands
held and use the bathroom unaided. At 5 months she
climbed stairs with a rail and continues to improve. Walk-
ing was achieved in all 3 despite ongoing knee ﬂexion con-
tractures. Improvement in functional ability was often
Table 1
Clinical demographics of DOK7 cohort.
Patient Age at onset; age salbutamol started Sex Parental consanguinity DOK7 mutation analysis
1 Birth; 5.9 year f No c.325G>T c.596delT
2 18 m; 8.9 year f No c.101–24_141del: 176_206delinsAG c.1124_1127dupTGCC
3 Birth; 5.8 year f No c.101–24_141del: 176_206delinsAG c.1124_1127dupTGCC
4 Birth; 10.9 year m Yes c.415G>C c.415G>C
5 Birth; 13.8 year m No c.1124_1127dupTGCC c.513C>T
6 Birth 15.1 year m No c.1124_1127dupTGCC c.533–37_c.533–11del27
7 3 m; 10.5 year f No c.1124_1127dupTGCC c.512G>A
8 Birth; 9.9 year f No c.54+25_39del15intron1 c.1263delC
9 18 m; 8 year f No c.601.C>T c.1142_1127dupTGCC
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ferent child’. Ptosis, when present, appeared to respond less
well to treatment with only 2 reporting an improvement.3.2. Eﬀect of salbutamol on timed tests
Changes in functional measures (timed arm raise, timed
rise from sitting or lying and timed 10 m) for each individ-
ual are illustrated in Fig. 1(a–c). Sustained arm raise
improved over the ﬁrst year in all children (Fig. 1a). The0 
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6 min walk test (6MWT). Results from patient 4 at baseline
and after 1, 3 and 28 months on salbutamol are shown in
Fig 1(d). There was improved walking distance and
reduced fatigue for individual laps following 1 and
3 months of salbutamol which was still sustained at follow
up after 28 months on treatment. Unfortunately, baseline
values were not available pre-salbutamol for 3 other chil-
dren in whom 6MWT was subsequently performed.
Results of the number of repeated ‘sit to stand’ in 1 min
showed a dramatic improvement in the 3 non-ambulant
children, who were unable to perform this test pre-salbuta-
mol, but completed 19, 15 and 32 ‘sit to stands’, respec-
tively at their last assessment. For 4 ambulant children in
whom serial data were available, the number of ‘sit to
stand’ achieved in 1 min showed a range of improvement
over treatment, with the percentage increment from the ini-
tial to the latest number achieved ranging from 16% to 65%
as follows: patient 1, 25–34 (36%); patient 2, 18–21 (16%);
patient 3, 20–33 (65%); patient 8, 15–18 (20%). Grip
myometry was measured in 7/9 children, with serial values
in 5. Results were variable, with some younger children
having diﬃculty using the myometer. Repeating the grip
myometry test 8 times in succession at each assessment
demonstrated a decrease between the ﬁrst and eighth values
(repeated as a possible indication of fatigue) in only 4 of 18
measurements: patient 5: a decrease of 15% at 16 m; patient
6, a decrease of 33% at 8 months; patient 7, a decrease of
15% and 33%, at 5 and 12 months post salbutamol, respec-
tively. Maximum myometry strength (the highest of 8
scores at each assessment) improved marginally with salbu-
tamol treatment in four children who had serial measures,
the percentage increment from the initial to last assessment
ranging from 4% to 7% for patients 1,2,3 and 7. Maximum
grip myometry force in patient 5 increased by 95% (from 65
to 127 Newtons) between 12 and 16 months on salbutamol
(aged 13 years 9 months and 14 years 1 month, respec-
tively). Mean myometry scores (an average of the 8 scores
at each assessment) increased by a percentage of 14% in
patient 1, 18% in patient 2, unchanged in patient 3, 91%
in patient 5 and 2% in patient 7. Likewise, timed upgaze
gave variable results, ranging from not possible at all due
to ptosis (patient 3) to sustained for a full minute (patients
2,6), with other children showing ﬂuctuation in values over
treatment with no consistent pattern.3.3. Adverse reactions during therapy
All children remained on treatment without noteworthy
adverse eﬀects. One child reported occasional palpitations
after 18 months of treatment, but cardiovascular examina-
tion and ECG monitoring were normal. The two sisters
had muscle cramps on exercise and at night prior to salbu-
tamol treatment. This became more marked on salbutamol.
Reduction of the salbutamol dose was considered, but
rejected by the family as the beneﬁt in functional improve-ment was felt to outweigh the disadvantage of increased
cramps.
4. Discussion
Oral salbutamol administered for at least one month
was found to improve muscle function in nine children with
DOK7 congenital myasthenic syndrome (CMS), without
notable adverse eﬀects. All reported an increase in stamina
and function, and this was conﬁrmed on the timed func-
tional assessments. Improvement was reported at 1 month
but continued for a further 5–17 months. Remarkably,
children who had been non-ambulant for many years
acquired the ability to walk independently after salbutamol
was administered. The functional improvement observed is
not typical of the natural history of the disease. Mutations
in DOK7 result in an endplate synaptopathy often associ-
ated with a slow, progressive decline in walking and run-
ning ability during childhood [2], possible loss of
ambulation in childhood, adolescence or adulthood [2–4]
and characterised by small, simpliﬁed and unstable neuro-
muscular junctions [1,4]. It is diﬃcult to deduce from this
small series and the short time-frame of study whether
introduction of salbutamol at a younger age will improve
mobility over the long term. However it is noteworthy that
two of our non-ambulant patients (5 and 6) became wheel-
chair dependent between the ages of 10 and 12 years. By
contrast, all of the ambulant children in this series on sal-
butamol are now over 9 years of age (three are aged 12,
13 and 14 years) and none of them require wheelchair assis-
tance even for distances. The development of contractures
in our weaker, non-ambulant children has also limited
resumption of mobility, so that introduction of salbutamol
at an early age, before decline in mobility and especially
before the pubertal growth spurt, would be a pragmatic
recommendation. Future studies with muscle MRI may
help determine whether ﬁxed myopathy develops over time
in DOK7 CMS and whether this can be inﬂuenced by early
salbutamol treatment.
The improvement in muscle function that we observed
with salbutamol is similar to that reported with ephedrine
[4,5] and is likely to be due to b2 adrenergic eﬀects. When
b2 agonists are used experimentally in a variety of inherited
neuromuscular disorders muscle function is improved
[5–10]. b2 receptors act through the G-protein second mes-
senger pathway to induce an increase in intracellular cyclic
AMP, and subsequently activate protein kinase A and
potentially inhibit proteolytic pathways. A second mecha-
nism of action is through the phosphatidylinositol 3-kinase
pathway leading to the activation of the serine-threonine
kinase Akt that phosphorylates numerous intracellular tar-
gets [11,15].
Dok-7 is a key component of the muscle-speciﬁc tyro-
sine kinase (MuSK) signalling pathway and is essential
for neuromuscular synaptogenesis [12] and for maintaining
synaptic structure. Activation of MuSK depends on auto-
phosphorylation initiated by neural derived Agrin but is
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MuSK monomers [16]. One of the downstream eﬀects of
MuSK itself is the phosphorylation of the acetylcholine
receptor b subunit, which facilitates binding of the Rapsyn
anchor protein. b2 agonists activate cAMP-protein kinase
A that is thought to feed into the MuSK signalling path-
way at the neuromuscular junction [13,14]. The salbuta-
mol-induced increase in kinase activity may partially
compensate for the reduced MuSK signalling resulting
from impaired Dok-7 function and thus provide a compen-
satory mechanism to stabilise the endplate. Indeed, b2
agonists appear to work best in the congenital myasthenic
syndromes associated with disrupted endplate structure
such as in the DOK7 synaptopathy or endplate acetylcho-
linesterase deﬁciency [10].
CMS are rare disorders and therefore small patient
numbers available for randomised controlled trials will
always limit studies of treatment eﬃcacy. As reported in
a previous study of ephedrine in DOK7 CMS, outcome
measures may not fully reﬂect functional beneﬁt [5]. Out-
comes in children also need to take account of muscle func-
tion changes with age due to natural motor development
and more variable motivation than in adults. In autoim-
mune myasthenia there are well-established outcome mea-
sures from questionnaires (e.g. MG-ADL) and timed tests
of muscle function (e.g. QMG score) but none have been
validated in children or in CMS. We explored the use of
several timed tests, which are used commonly in paediatric
neuromuscular assessments to reﬂect functional motor
ability (timed rise from sitting or lying, timed 10 m run)
and the compounding eﬀect of muscle fatigue (repeated
sit to stand in 1 min, timed arm raise in forward ﬂexion
at the shoulder, timed upgaze and repeated grip myome-
try). We selected these tests as a minimum screen to use
in the outpatient setting where time and motivation of
younger children may be limited.
Timed arm raise was helpful in most, but the timed rise
from ﬂoor and 10 m timed walk were only useful in those
who were weak at baseline. We found repeated grip myom-
etry to be of limited value in young children, who found it
diﬃcult to grip the myometer adequately. Although values
increased during the treatment period in others, this may
reﬂect age-related maturation. We were unable to consis-
tently demonstrate fatigue of grip strength on repeated
myometry, but we have done so in children with other
CMS or autoimmune myasthenia, so that this may reﬂect
the predilection for weakness and fatigue to aﬀect proximal
limb girdle muscles in DOK7 CMS. Timed upgaze was like-
wise of limited value in assessing the eﬀect of treatment in
DOK7 children – some had no ptosis or upgaze fatigue at
baseline and, when ptosis was present, it proved less
responsive to treatment than limb girdle weakness and fati-
gue. All families reported improved endurance and fewer
falls with salbutamol treatment, this was reﬂected in a sub-
stantial improvement in the 6MWT in the one child tested
longitudinally. The 6MWT may therefore prove to be abetter objective marker for future CMS treatment studies
and we have now introduced this as part of our clinic
assessment. We noted ﬂuctuations in timed tests due to dif-
ﬁculties with motivation, mild intercurrent illness and fati-
gue induced by travel on the clinic day. The development of
validated timed tests for parents of CMS children to use at
home to monitor progress should provide a useful adjunct
to clinic testing.
This study found that oral salbutamol appears to be well
tolerated and improves muscle function in children with
DOK7 CMS. Although results should be interpreted with
caution because of the relatively small sample size and lack
of placebo control, our ﬁndings reinforce the report of sim-
ilar beneﬁcial eﬀects of albuterol in adults with DOK7
CMS [10].
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